<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826525</url>
  </required_header>
  <id_info>
    <org_study_id>D5590C00002</org_study_id>
    <nct_id>NCT02826525</nct_id>
  </id_info>
  <brief_title>AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.</brief_title>
  <official_title>Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/IIa, randomized, single-blind, placebo-controlled, multiple-ascending dose
      study conducted at a single site. The study plans to include up to approximately 46 evaluable
      subjects with Type 2 Diabetes Mellitus (HbA1c 7-11%) and Non-Alcoholic Fatty Liver disease
      (liver fat content &gt; = 8%) on metformin monotherapy.

      Three initial cohorts are planned:

        -  Cohort 1: 6 subjects receiving AZD4076 and 4 subjects receiving placebo

        -  Cohort 2: 12 subjects receiving AZD4076 and 10 subjects receiving placebo

        -  Cohort 3: 10 subjects receiving AZD4076 and 10 subjects receiving placebo, with the
           possibility to add additional subjects if drop-out rates are higher than expected

      Pending review by SRC, an additional 2 cohorts, each consisting of 18 evaluable subjects may
      be included in the study.

      The primary objectives of this clinical trial are to investigate the safety and tolerability
      of AZD4076 following subcutaneous administration of multiple ascending doses; to assess the
      effect of AZD4076 on whole body insulin sensitivity using hyperinsulinemic euglycemic clamp
      with tracer technique; and to assess the effect of AZD4076 on liver fat content using
      magnetic resonance imaging. Secondary objectives of this trial are to characterize multiple
      dose PK of AZD4076 and its longmer and shortmer metabolites and assess the time required to
      reach steady state and the degree of accumulation; to assess the efficacy of AZD4076 on
      24-hour glucose; and to assess the effect of AZD4076 on homeostatic model assessment insulin
      resistant (HOMA-IR) and Matsuda index.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/IIa, randomized, single-blind, placebo-controlled, multiple-ascending dose
      study conducted at a single site. The study plans to include up to approximately 46 evaluable
      subjects with Type 2 Diabetes Mellitus (HbA1c 7-11%) and Non-Alcoholic Fatty Liver disease
      (liver fat content &gt; = 8%) on metformin monotherapy

      Three initial cohorts are planned:

        -  Cohort 1: 6 subjects receiving AZD4076 and 4 subjects receiving placebo

        -  Cohort 2: 12 subjects receiving AZD4076 and 10 subjects receiving placebo

        -  Cohort 3: 10 subjects receiving AZD4076 and 10 subjects receiving placebo, with the
           possibility to add additional subjects if drop-out rates are higher than expected.

      Pending review by SRC, an additional 2 cohorts, each consisting of 18 evaluable subjects may
      be included in the study.

      The planned study consists of a screening visit, followed by 12 subsequent study visits.
      There will be a total of three residential periods: (1) Loading phase of the treatment (visit
      2, days -4 to 14), (2) maintenance phase of treatment (visit 6, days 42-43), and (3) 8 weeks
      post-first dose of study drug (visit 9, days 53-56). Dosing of study drug will take place on
      days 1, 3, 5, 7, and 9 in the loading phase; and on days 14, 21, 28, 35, and 42 during the
      maintenance phase. Following the maintenance phase, subjects will have four follow-up visits.

      Study Objectives:

      The primary objectives of this clinical trial are to investigate the safety and tolerability
      of AZD4076 following subcutaneous administration of multiple ascending doses; to assess the
      effect of AZD4076 on whole body insulin sensitivity using hyperinsulinemic euglycemic clamp
      with tracer technique; and to assess the effect of AZD4076 on liver fat content using
      magnetic resonance imaging. Secondary objectives of this trial are to characterize multiple
      dose PK of AZD4076 and its longmer and shortmer metabolites and assess the time required to
      reach steady state and the degree of accumulation; to assess the efficacy of AZD4076 on
      24-hour glucose; and to assess the effect of AZD4076 on homeostatic model assessment insulin
      resistant (HOMA-IR) and Matsuda index.

      Study Population:

      Subjects participating in this study are adult males and females of non-child bearing
      potential, who are 18-70 years of age, body mass index 23-40 kg/m2, diagnosed with T2DM who
      are inadequately controlled (HbA1C 7-11%) on a stable metformin regimen, and who have hepatic
      steatosis (defined as liver fat content of &gt;=8% per MRI).

      Duration of treatment:

      The screening visit will occur within 42 days prior to the administration of the study drug.
      Total length of the treatment period is 6 weeks. The treatment period is divided in two
      phases: the loading phase, in which participants will receive the study drug every other day
      for 9 days (Days 1, 3, 5 , 7 and 9); thereafter subjects will enter the maintenance phase,
      where dosing will occur once weekly for four weeks (Days 14, 21, 28, 35 and 42). To ensure
      safety, subjects will be followed for approximately 5 months post the last dose of study
      drug.

      Investigational product, dosage and mode of administration:

      The study will utilize two study drugs: AZD4076 and placebo. Both drugs will be administered
      subcutaneously in the abdomen.

      Safety analysis:

      The key outcomes for the safety analyses are: adverse events, vital signs, safety laboratory
      parameters, ECGs, telemetry; and structured neurological and physical examination, as well as
      injection site assessment. Pharmacodynamic parameters will be derived from data generated
      from the clamp procedure, MRI, HOMA, OGTT and 24-hour glucose AUC. For pharmacokinetic
      parameters, plasma and urine concentrations of AZD4076 and its metabolites will be measured
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessing the number of participants with adverse events</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessment of blood pressure</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessment of pulse</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessment of oral temperature</measure>
    <time_frame>From day -2 until day 42</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessment of electrocardiogram readings</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readings</measure>
    <time_frame>From predose until 24 hours post-dose on days 1 and 42</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability AZD4076 by assessment of physical examination</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>Percentage of patients with abnormal physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessing the injection site</measure>
    <time_frame>From day 1 until day 42</time_frame>
    <description>Percentage of patients with dermatological adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessing the number of adverse events</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessing hematology</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessing clinical chemistry</measure>
    <time_frame>From screening until 26 weeks post first dose</time_frame>
    <description>Percentage of patients with clinically significant changes in laboratory tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety and tolerability of AZD4076 by assessing urinalysis</measure>
    <time_frame>From screening until 26 weeks post-first dose</time_frame>
    <description>To assess the safety and tolerability of multiple ascending doses of AZD4076</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose infusion rate at hyperinsulinemic clamp</measure>
    <time_frame>Day -1 and 56 days post first dose</time_frame>
    <description>To assess the effect of AZD4076 on whole body insulin sensitivity using hyperinsulinemic euglycemic clamp with tracer technique</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in liver fat content (%) per MRI</measure>
    <time_frame>Screening and 54 days post first dose</time_frame>
    <description>To assess the effect of AZD4076 on liver fat content using magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour glucose area under the curve</measure>
    <time_frame>Day -2 and day 55</time_frame>
    <description>To assess the effect of AZD4076 on 24-hour glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>Day -2 and day 55</time_frame>
    <description>To assess the effect of AZD4076 on homeostatic model assessment insulin resistant (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Endogenous Glucose Production</measure>
    <time_frame>Day -1 and day 56</time_frame>
    <description>To assess the effect of AZD4076 on endogenous glucose production (EGP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Dosing day 1 and day 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by area under the curve to time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index</measure>
    <time_frame>Day -2 and day 55</time_frame>
    <description>To assess the effect of AZD4076 on Matusda Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Dosing day 1 and day 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by area under the curve to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Dosing day 1 and day 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Dosing day 1 and day 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by time to peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Day 1 and 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe% of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Dosing day 1 and day 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by fraction excreted in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae of AZD4076 and longmer and shortmer metabolites</measure>
    <time_frame>Dosing day 1 and day 42</time_frame>
    <description>To characterize pharmacokinetics of AZD4076 by amount excreted in urine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>T2DM With NAFLD</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive AZD4076</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4076</intervention_name>
    <description>Investigational product</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          2. Males or females of non-child bearing potential.

          3. Age 18-70 years with suitable veins for cannulation or repeated venipuncture.

          4. BMI 23-40 kg/m2 inclusive.

          5. Diagnosed T2D (HbA1c 7-11%) treated with a stable dose of metformin for at least one
             month prior to screening.

          6. Hepatic steatosis of â‰¥8%.

        Exclusion criteria

          1. Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of the first administration of IMP.

          2. History or presence of hepatic or renal disease (with the exception of hepatic
             steatosis).

          3. Presence of acute proliferative retinopathy or maculopathy, severe gastroparesis,
             and/or severe neuropathy, in particular autonomic neuropathy.

          4. Clinically significant cardiovascular event within the last 6 months prior to
             screening.

          5. History or presence of significant neurological or psychiatric disease/mental illness
             (as assessed using the C-SSRS).

          6. History of malignancy within the last 5 years, excluding successful treatment of basal
             cell skin carcinoma or in situ carcinoma of cervix.

          7. Suspicion of or known Gilbert's syndrome.

          8. Supine systolic blood pressure greater than 160 mmHg or diastolic blood pressure
             greater than 95 mmHg confirmed in the screening period.

          9. Changes in any current medication (initiation, dose change or cessation) that may
             impact the study readouts (as judged by the Investigator) within three months prior to
             MRI assessment of steatosis screening. The criterion does not apply to medication
             prescribed for occasional use.

        10 Treatment with antidiabetics (except for metformin) during the last three months prior
        to screening or treatment with sulfonylurea (SU) drugs within the 4 weeks prior to
        screening.

        11. Used or plan to use drugs that cause weight loss, participating in, or have
        participated in weight loss program within the last 3 months.

        12. Use of anabolic steroids and systemic treatment with glucosteroids within three months
        prior to screening. Intra articular, topical, and inhaled steroids are permissible.

        13. Any confirmed clinically significant abnormalities in clinical chemistry, hematology,
        or urinalysis results, as judged by the Investigator.

        14. Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
        hepatitis C antibody and human immunodeficiency virus (HIV).

        15. Confirmed serum creatinine greater than the ULN. 16. A confirmed eGFR &lt;60 calculated
        according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

        17. Confirmed platelet count outside the normal range. 18. Confirmed ALT or AST greater
        than 1.5x ULN. 19. Confirmed total bilirubin greater than ULN 20. Any clinically
        significant abnormalities in rhythm, conduction or morphology of the resting ECG and any
        clinically significant abnormalities in the 12-lead ECG, as considered by the investigator
        that may interfere with the interpretation of QTc interval changes, including abnormal
        ST-T-wave morphology, particularly in the protocol defined primary lead, or left
        ventricular hypertrophy.

        21. Prolonged QTcF &gt; 450 ms for males and &gt; 470 ms for females or family history of long QT
        syndrome.

        22. PR(PQ) interval shortening &lt; 120 ms (PR &gt; 110 ms but &lt; 120 ms is acceptable if there is
        no evidence of ventricular pre-excitation.

        23. PR (PQ) interval prolongation (&gt; 240 ms) intermittent second (Wenckebach block while
        asleep is not exclusive) or third degree AV block, or AV dissociation.

        24. Persistent or intermittent complete bundle branch block (BBB) with QRS &gt; 120 ms.

        25. Known or suspected history of drug abuse within the past 5 years, as judged by the
        Investigator.

        26. Smokes &gt;10 cigarettes/day and unable to comply with the nicotine restriction during the
        study.

        27. History of alcohol abuse or excessive intake of alcohol. Definition of excessive
        intake: an average weekly intake of &gt;14 drinks/week for men or &gt;7 drinks/week for women.
        One drink is equivalent to (12 g alcohol) = 5 ounces (150 mL) of wine or 12 ounces (360 mL)
        of beer or 1.5 ounces (45 mL) of 80 proof distilled spirits.

        28. Positive screen for drugs of abuse at screening or admission to the unit or positive
        screen for alcohol at screening or on admission to the unit prior to the first
        administration of IMP.

        29. History of severe allergy/hypersensitivity or ongoing clinically significant
        allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to
        drugs with a similar chemical structure or class to AZD4076.

        30. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea), as judged
        by the Investigator.

        31. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks
        prior to the first administration of IMP.

        32. Plasma donation within one month of screening or any blood donation/blood loss &gt; 500 mL
        during the 56 days prior to screening.

        33. Has received another new chemical entity (defined as a compound which has not been
        approved for marketing) within one month of the administration of IMP in this study. The
        period of exclusion begins one month after the final dose or one month after the last visit
        whichever is the longest.

        34. Use of implants or devices that are incompatible with the MRI procedure. 35. Vulnerable
        subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or
        committed to an institution by governmental or juridical order.

        36. Involvement of any Astra Zeneca, PROFIL INSTITUTE or study site employee or their close
        relatives.

        37. Judgment by the Investigator that the subject should not participate in the study if
        they have any ongoing or recent (i.e., during the screening period) minor medical
        complaints that may interfere with the interpretation of study data or are considered
        unlikely to comply with study procedures, restrictions and requirements.

        38. Subjects not willing to comply with the dietary requirements in the study as judged by
        the Investigator.

        39. Subjects who cannot communicate reliably with the Investigator or designee. 40.
        Previous bone marrow transplant. 41. Non-leukocyte depleted whole blood transfusion within
        120 days of the date of the genetic sample collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Morrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

